<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>41 patients with hereditary and acquired antithrombin II deficiency received a substitution therapy with human plasma fraction of antithrombin III from the GDR blood-transfusion service </plain></SENT>
<SENT sid="1" pm="."><plain>In 6 patients a hereditary AT III deficiency was substituted and in this context the substitution in case of thromboses during pregnancy was explained </plain></SENT>
<SENT sid="2" pm="."><plain>35 patients with acquired AT III deficiency were substituted with AT III concentrate because of thromboembolic complication in the macro-circulatory system in case of AT III deficiency due to reduced synthesis, loss, increased consumption or a combination of these conditions or because of <z:chebi fb="0" ids="53092">DIC</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>The substitution effect was good </plain></SENT>
<SENT sid="4" pm="."><plain>Dosage and injection intervals depend on the clinical condition </plain></SENT>
<SENT sid="5" pm="."><plain>Side-effects have not been observed </plain></SENT>
</text></document>